Romosozumab has no impact on radiographic or clinical outcomes following hip fracture ORIF
J Bone Joint Surg Am.2020Hip fractures are one of the leading causes of disability worldwide, and continue to grow in numbers given the aging global population. When hip fractures are repaired with open reduction, internal fixation, there is concern about the bone quality and healing potential in this population. Thus, numerous different therapies have been investigated recently in an effort to promote bone healing in this context. in this study, the authors evaluated the effects of romosozumab, a monoclonal antibody. The authors randomized patients to placebo or one of three doses of romosozumab. Overall, there was no important differences in Timed Up and Go Test, radiographic healing, Harris Hip Score or pain scores between any of the groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
